AI assistant
Ambu Transaction in Own Shares 2016
3353_rns_2016-09-08_ca7c0171-4d20-48cf-9bab-61d101d11c79.pdf
Transaction in Own Shares
Open in viewerOpens in your device viewer
Ambu
Ideas that work for life
Buyback programme
On 19 August 2016, Ambu initiated a parallel share buyback programme for the purpose of hedging share-based incentive programmes.
The share buyback programme is expected to end on 30 September 2016 at the latest and comprise a total share buyback of up to 268,000 B-shares.
Under the share buyback programme, the following transactions were conducted in the period 30 August to 7 September 2016:
| Date | Number of B shares | Average market price | Transaction value |
|---|---|---|---|
| Accumulated latest announcement | 97,816 | 327.2 | 32,009,215 |
| 30 August 2016 | 5,000 | 328.1 | 1,640,307 |
| 31 August 2016 | 1,000 | 331.3 | 331,276 |
| 1 September 2016 | - | - | - |
| 2 September 2016 | 2,000 | 338.2 | 676,353 |
| 5 September 2016 | 3,000 | 345.0 | 1,035,050 |
| 6 September 2016 | 2,000 | 343.6 | 687,189 |
| 7 September 2016 | 2,000 | 342.4 | 684,706 |
| Accumulated under the programme | 112,816 | 328.5 | 37,064,096 |
Following the above transactions, Ambu owns a total of 1,210,288 Class B shares with a nominal value of DKK 2.5 each, corresponding to 2.5% of the share capital. The total number of Class A and Class B shares in the company is 48,370,720 including treasury shares.
Contact
Lars Marcher, President & CEO, tel. +45 5136 2490, email: [email protected]
About Ambu
Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the aScope™ endoscope – the world's first single-use flexible video scope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medical companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,300 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.
Ambu
Company announcement no. 40 2015/16
8 September 2016